Vivani Medical is a preclinical stage biopharmaceutical company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable delivery of a range of medicines to treat chronic diseases. Co.'s pipeline programs are: NPM-119, which is in preclinical stage development for the treatment of patients with type 2 diabetes; OKV-119, which is under development for the treatment of obese and diabetic companion cats; NPM-139, which is in feasibility testing for the treatment of patients with obesity; and NPM-159, which is in feasibility testing for the treatment of patients with non-alcoholic steatohepatitis. The VANI stock yearly return is shown above.
The yearly return on the VANI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VANI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|